• 1
    Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 17331745.
  • 2
    Hoofnagle JH, di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347356.
  • 3
    Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336: 18551859.
  • 4
    Szmuness W, Stevens CE, Harley EJ, Zang EA, Alter HJ, Taylor PE, DeVera A, et al. Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection. N Engl J Med 1982; 307: 14811486.
  • 5
    Desombere I, Willems A, Leroux-Roels G. Response to hepatitis B vaccine: multiple HLA genes are involved. Tissue Antigens 1998; 51: 593604.
  • 6
    Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med 1997; 336: 196204.
  • 7
    Weissman JY, Tsuchiyose MM, Tong MJ, Co R, Chin K, Ettenger RB. Lack of response to recombinant hepatitis B vaccine in nonresponders to the plasma vaccine. JAMA 1988; 260: 17341738.
  • 8
    McDermott AB, Madrigal JA, Sabin CA, Zuckerman JN, Cohen SB. The influence of host factors and immunogenetics on lymphocyte responses to Hepagene vaccination. Vaccine 1999; 17: 13291337.
  • 9
    Chedid MG, Deulofeut H, Yunis DE, Lara-Marquez ML, Salazar M, Deulofeut R, Awdeh Z, et al. Defect in Th1-like cells of nonresponders to hepatitis B vaccine. Hum Immunol 1997; 58: 4251.
  • 10
    Shokrgozar MA, Shokri F. Enumeration of hepatitis B surface antigen-specific B lymphocytes in responder and non-responder normal individuals vaccinated with recombinant hepatitis B surface antigen. Immunology 2001; 104: 7579.
  • 11
    Livingston BD, Alexander J, Crimi C, Oseroff C, Celis E, Daly K, Guidotti LG, et al. Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans. J Immunol 1999; 162: 30883095.
  • 12
    Vingerhoets J, Vanham G, Kestens L, Penne G, Leroux-Roels G, Gigase P. Deficient T-cell responses in non-responders to hepatitis B vaccination: absence of TH1 cytokine production. Immunol Lett 1994; 39: 163168.
  • 13
    Kardar GA, Jeddi-Tehrani M, Shokri F. Diminished Th1 and Th2 cytokine production in healthy adult nonresponders to recombinant hepatitis B vaccine. Scand J Immunol 2002; 55: 311314.
  • 14
    Deulofeut H, Iglesias A, Mikael N, Bing DH, Awdeh Z, Yunis J, Marcus-Bagley D, et al. Cellular recognition and HLA restriction of a midsequence HBsAg peptide in hepatitis B vaccinated individuals. Mol Immunol 1993; 30: 941948.
  • 15
    Egea E, Iglesias A, Salazar M, Morimoto C, Kruskall MS, Awdeh Z, Schlossman SF, et al. The cellular basis for lack of antibody response to hepatitis B vaccine in humans. J Exp Med 1991; 173: 531538.
  • 16
    Hohler T, Reuss E, Evers N, Dietrich E, Rittner C, Freitag CM, Vollmar J, et al. Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis A virus: a vaccination study in twins. Lancet 2002; 360: 991995.
  • 17
    Lango-Warensjo A, Cardell K, Lindblom B. Haplotypes comprising subtypes of the DQB1*06 allele direct the antibody response after immunisation with hepatitis B surface antigen. Tissue Antigens 1998; 52: 374380.
  • 18
    Rogers AS, Futterman DK, Moscicki AB, Wilson CM, Ellenberg J, Vermund SH. The REACH Project of the Adolescent Medicine HIV/AIDS Research Network: design, methods, and selected characteristics of participants. J Adolesc Health 1998; 22: 300311.
  • 19
    Wilson CM, Houser J, Partlow C, Rudy BJ, Futterman DC, Friedman LB. The REACH (Reaching for Excellence in Adolescent Care and Health) project: study design, methods, and population profile. J Adolesc Health 2001; 29: 818.
  • 20
    Wilson CM, Ellenberg JH, Sawyer MK, Belzer M, Crowley-Nowick PA, Puga A, Futterman DC, et al. Serologic response to hepatitis B vaccine in HIV infected and high-risk HIV uninfected adolescents in the REACH cohort. Reaching for Excellence in Adolescent Care and Health. J Adolesc Health 2001; 29: 123129.
  • 21
    Douglas SD, Rudy B, Muenz L, Moscicki AB, Wilson CM, Holland C, Crowley-Nowick P, et al. Peripheral blood mononuclear cell markers in antiretroviral therapy-naive HIV-infected and high risk seronegative adolescents. Adolescent Medicine HIV/AIDS Research Network. AIDS 1999; 13: 16291635.
  • 22
    Tang J, Lobashevsky E, Wilson CM, Allen S, Musonda R, Kaslow RA. Reference-strand conformation analyses (RSCA) of HLA-A and -B variants in several non-Caucasian populations. Hum Immunol 2001; 62(Suppl 1): S148.
  • 23
    Tang J, Tang S, Lobashevsky E, Myracle AD, Fideli U, Aldrovandi G, Allen S, et al. Favorable and unfavorable HLA class I alleles and haplotypes in Zambians predominantly infected with clade C human immunodeficiency virus type 1. J Virol 2002; 76: 82768284.
  • 24
    Tang J, Wilson CM, Meleth S, Myracle A, Lobashevsky E, Mulligan MJ, Douglas SD, et al. Host genetic profiles predict virological and immunological control of HIV-1 infection in adolescents. AIDS 2002; 16: 22752284.
  • 25
    Louie LG, Wallenstein E, Schmelzer K, Kearney FC, Crowley J, Peste-Tsilimidou C, Spyropoulou-Vlachou M, et al. Report of the anthropology group from the Cytokine Polymorphism Component. In: HansenJ, DupontB, eds. HLA 2002: Proceedings of 13th International Histocompatibility Workshop and Congress. Volume II. Seattle: IHWG Press, 2003; in press.
  • 26
    Morahan G, Huang D, Wu M, Holt BJ, White GP, Kendall GE, Sly PD, et al. Association of IL12B promoter polymorphism with severity of atopic and non-atopic asthma in children. Lancet 2002; 360: 455459.
  • 27
    Morahan G, Boutlis CS, Huang D, Pain A, Saunders JR, Hobbs MR, Granger DL, et al. A promoter polymorphism in the gene encoding interleukin-12 p40 (IL12B) is associated with mortality from cerebral malaria and with reduced nitric oxide production. Genes Immun 2002; 3: 414418.
  • 28
    Hadler SC, Francis DP, Maynard JE, Thompson SE, Judson FN, Echenberg DF, Ostrow DG, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986; 315: 209214.
  • 29
    Just JJ, King MC, Thomson G, Klitz W. African-American HLA class II allele and haplotype diversity. Tissue Antigens 1997; 49: 547555 [corrected version of Tissue Antigens 1996;48:636–644].
  • 30
    Cao K, Hollenbach J, Shi X, Shi W, Chopek M, Fernandez-Vina MA. Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum Immunol 2001; 62: 10091030.
  • 31
    Gibson AW, Edberg JC, Wu J, Westendorp RG, Huizinga TW, Kimberly RP. Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus. J Immunol 2001; 166: 39153922.
  • 32
    Ejiri S, Eguchi Y, Kishida A, Ishigami F, Kurumi Y, Tani T, Kodama M. Cellular distribution of thrombomodulin as an early marker for warm ischemic liver injury in porcine liver transplantation: protective effect of prostaglandin I2 analogue and tauroursodeoxycholic acid. Transplantation 2001; 71: 721726.
  • 33
    Thio CL, Thomas DL, Carrington M. Chronic viral hepatitis and the human genome. HEPATOLOGY 2000; 31: 819827.
  • 34
    Hoffmann SC, Stanley EM, Darrin Cox E, Craighead N, DiMercurio BS, Koziol DE, Harlan DM, et al. Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28-stimulated peripheral blood lymphocytes. Transplantation 2001; 72: 14441450.
  • 35
    Thursz MR, Thomas HC, Greenwood BM, Hill AV. Heterozygote advantage for HLA class-II type in hepatitis B virus infection. Nat Genet 1997; 17: 1112.
  • 36
    Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, Goedert JJ, Kaslow R, et al. HLA and HIV-1: heterozygosity advantage and B*35-Cw*04 disadvantage. Science 1999; 283: 17481752.
  • 37
    Tang J, Costello C, Keet IPM, Rivers C, LeBlanc S, Karita E, Allen S, et al. HLA class I homozygosity accelerates disease progression in human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 1999; 15: 317324.
  • 38
    Font J, Garcia-Carrasco M, Ramos-Casals M, Aldea AI, Cervera R, Ingelmo M, Vives J, et al. The role of interleukin-10 promoter polymorphisms in the clinical expression of primary Sjogren's syndrome. Rheumatology (Oxford) 2002; 41: 10251030.
  • 39
    Abbas AK, Lichtman AH, Pober JS. Cellular and Molecular Immunology. 4th ed. New York: W.B. Saunders Company, 2000: 553.
  • 40
    Desombere I, Van der Wielen M, Van Damme P, Stoffel M, De Clercq N, Goilav C, Leroux-Roels G. Immune response of HLA DQ2 positive subjects, vaccinated with HBsAg/AS04, a hepatitis B vaccine with a novel adjuvant. Vaccine 2002; 20: 25972602.
  • 41
    Caillat-Zucman S, Gimenez JJ, Wambergue F, Albouze G, Lebkiri B, Naret C, Moynot A, et al. Distinct HLA class II alleles determine antibody response to vaccination with hepatitis B surface antigen. Kidney Int 1998; 53: 16261630.
  • 42
    Meuer SC, Dumann H, Meyer zum Buschenfelde KH, Kohler H. Low-dose interleukin-2 induces systemic immune responses against HBsAg in immunodeficient non-responders to hepatitis B vaccination. Lancet 1989; 1: 1518.
  • 43
    Chow YH, Huang WL, Chi WK, Chu YD, Tao MH. Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2. J Virol 1997; 71: 169178.
  • 44
    Schirmbeck R, Reimann J. Enhancing the immunogenicity of exogenous hepatitis B surface antigen-based vaccines for MHC-I-restricted T cells. Biol Chem 1999; 380: 285291.
  • 45
    Dahmen A, Herzog-Hauff S, Bocher WO, Galle PR, Lohr HF. Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B. J Med Virol 2002; 66: 452460.
  • 46
    Du DW, Jia ZS, Li GY, Zhou YY. HBV DNA vaccine with adjuvant cytokines induced specific immune responses against HBV infection. World J Gastroenterol 2003; 9: 108111.
  • 47
    Schirmbeck R, Reimann J. Modulation of gene-gun-mediated Th2 immunity to hepatitis B surface antigen by bacterial CpG motifs or IL-12. Intervirology 2001; 44: 115123.
  • 48
    Genevay S, Di Giovine FS, Perneger TV, Silvestri T, Stingelin S, Duff G, Guerne PA. Association of interleukin-4 and interleukin-1B gene variants with Larsen score progression in rheumatoid arthritis. Arthritis Rheum 2002; 47: 303309.
  • 49
    Nakayama EE, Meyer L, Iwamoto A, Persoz A, Nagai Y, Rouzioux C, Delfraissy JF, et al. Protective effect of interleukin-4 -589T polymorphism on human immunodeficiency virus type 1 disease progression: relationship with virus load. J Infect Dis 2002; 185: 11831186.
  • 50
    Modi WS, O'Brien TR, Vlahov D, Buchbinder S, Gomperts E, Phair J, O'Brien SJ, et al. Haplotype diversity in the interleukin-4 gene is not associated with HIV-1 transmission and AIDS progression. Immunogenetics 2003; 55: 157164.
  • 51
    Vasilescu A, Heath SC, Ivanova R, Hendel H, Do H, Mazoyer A, Khadivpour E, et al. Genomic analysis of Th1-Th2 cytokine genes in an AIDS cohort: identification of IL4 and IL10 haplotypes associated with the disease progression. Genes Immun 2003; 4: 441449.
  • 52
    Poovorawan Y, Pongpunlert W, Theamboonlers A, Vimolgej L, Chumdermpadetsuk S, Vandepapeliere P, Safary A. Randomized, single-blind comparison of the immunogenicity and reactogenicity of 20 micrograms and 10 micrograms doses of hepatitis B vaccine in adolescents. Southeast Asian J Trop Med Public Health 1993; 24: 255259.
  • 53
    Schiff GM, Sherwood JR, Zeldis JB, Krause DS. Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescents. J Adolesc Health 1995; 16: 1217.
  • 54
    Bruguera M, Cremades M, Salinas R, Costa J, Grau M, Sans J. Impaired response to recombinant hepatitis B vaccine in HIV-infected persons. J Clin Gastroenterol 1992; 14: 2730.
  • 55
    Zuin G, Principi N, Tornaghi R, Paccagnini S, Re M, Massironi E, Ragni MC. Impaired response to hepatitis B vaccine in HIV infected children. Vaccine 1992; 10: 857860.
  • 56
    Valentine FT, Kundu S, Haslett PA, Katzenstein D, Beckett L, Spino C, Borucki M, et al. A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with > or = 400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137). J Infect Dis 1996; 173: 13361346.
  • 57
    Nakayama EE, Hoshino Y, Xin X, Liu H, Goto M, Watanabe N, Taguchi H, et al. Polymorphism in the interleukin-4 promoter affects acquisition of human immunodeficiency virus type 1 syncytium-inducing phenotype. J Virol 2000; 74: 54525459.
  • 58
    Haukim N, Bidwell JL, Smith AJ, Keen LJ, Gallagher G, Kimberly R, Huizinga T, et al. Cytokine gene polymorphism in human disease: on-line databases, supplement 2. Genes Immun 2002; 3: 313330.
  • 59
    Yee LJ, Tang J, Gibson AW, Kimberly R, Van Leeuwen DJ, Kaslow RA. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. HEPATOLOGY 2001; 33: 708712.